Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables JW SH SC 247 24th Mar, 2025
Short-term setback results in earnings cut; maintain Buy with TP of IDR2,350
4Q24 result miss: lower GPM and higher-than-expected opex
AMRT’s sales growth in 2024 remained solid at +10% y-y, demonstrating its resilience despite a challenging macroeconomic backdrop. However, net margin declined by 50bp y-y, leading to an earnings miss. We believe the unexpected decline in GPM (-10bp y-y) was largely due to a higher-than-expected rollout of promotions, as maintaining SSSG momentum (+5.2% y-y in 2024) was a key priority for the company. Meanwhile, the overall increase in opex as a percentage of sales (+40bp y-y) was mainly attributed to investments in four additional DCs, chillers, and cash deposit machines.
Key for 2025F: Balancing between sales growth and profitability margin
We expect AMRT to focus this year on striking a better balance between promotional activities, sales growth, and profitability margin. However, achieving this will be challenging given weak consumer purchasing power. As a result, we lower our GPM expansion estimate to 10bs (from 20bp) for 2025F. While we expect opex as a percentage of sales to ease as the utilization of recent investments should improve, the higher-than-expected minimum wage increase (+6.5% y-y) could add further pressure. Consequently, we now anticipate flat y-y opex as a percentage of sales for 2025F.
Maintain Buy with lower TP of IDR2,350 (+21% upside)
We downgrade our 2025F/26F earnings assumptions by 21%/23%. We now base our TP on a 2025F P/E of 27.6x, equal to its five-year average (from 2025F P/E of 33.4x, +1 SD, previously). This adjustment reflects the lower earnings growth we now expect at +15% for 2024-2027F, compared to +19% for 2022-2024. AMRT’s average P/E in 2023-2024 was around 35x. Given the decline in growth expectations from 19% to 15%, a corresponding reduction in the target P/E to 27.6x (-21%) is justified, in our view. As a result, we lower our TP to IDR2,350 (from IDR3,600).
Despite this, we believe that AMRT continues to deserve a premium valuation due to its robust business model, duopoly market position, and resilience in challenging macroeconomic conditions. Evidenced by its continuous operating cashflow (OCF) expansion (Fig. 5). Key downside risks include prolonged weakness in consumer purchasing power, as well as the potential for significant foreign capital outflows, given that the local-to-foreign investor ratio in AMRT stands at approximately 1:8/9. The company’s ability to deliver higher growth could result in potential P/E rerating, in our view.
Year-end 31 Dec | FY24 | FY25F | FY26F | FY27F | |||
Currency (IDR) | Actual | Old | New | Old | New | Old | New |
Revenue (bn) | 118,227 | 128,887 | 129,515 | 140,701 | 143,092 | 0 | 157,019 |
Reported net profit (bn) | 3,148 | 4,474 | 3,532 | 5,332 | 4,091 | 0 | 4,768 |
Normalised net profit (bn) | 3,148 | 4,474 | 3,532 | 5,332 | 4,091 | 0 | 4,768 |
FD normalised EPS | 75.81 | 107.75 | 85.06 | 128.41 | 98.52 | 114.83 | |
FD norm. EPS growth (%) | -7.5 | 18.8 | 12.2 | 19.2 | 15.8 | 16.6 | |
FD normalised P/E (x) | 25.6 | – | 22.8 | – | 19.7 | – | 16.9 |
EV/EBITDA (x) | 11.0 | – | 9.8 | – | 8.5 | – | 7.2 |
Price/book (x) | 4.9 | – | 4.3 | – | 3.7 | – | 3.2 |
Dividend yield (%) | 1.5 | – | 1.4 | – | 1.6 | – | 1.8 |
ROE (%) | 20.4 | 24.1 | 20.1 | 24.2 | 20.3 | 20.5 | |
Net debt/equity (%) | net cash | net cash | net cash | net cash | net cash | net cash | |
Income statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY23 | FY24 | FY25F | FY26F | FY27F | ||||||||||||||
Revenue | 106,945 | 118,227 | 129,515 | 143,092 | 157,019 | ||||||||||||||
Cost of goods sold | -83,879 | -92,862 | -101,669 | -112,097 | -122,748 | ||||||||||||||
Gross profit | 23,066 | 25,365 | 27,846 | 30,995 | 34,272 | ||||||||||||||
SG&A | -19,780 | -22,384 | -24,369 | -26,893 | -29,406 | ||||||||||||||
Employee share expense | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Operating profit | 3,286 | 2,982 | 3,477 | 4,102 | 4,865 | ||||||||||||||
EBITDA | 6,913 | 7,138 | 7,885 | 8,905 | 10,049 | ||||||||||||||
Depreciation | -1,516 | -1,803 | -1,903 | -2,117 | -2,309 | ||||||||||||||
Amortisation | -2,111 | -2,354 | -2,505 | -2,686 | -2,875 | ||||||||||||||
EBIT | 3,286 | 2,982 | 3,477 | 4,102 | 4,865 | ||||||||||||||
Net interest expense | -87 | -19 | 2 | 37 | 91 | ||||||||||||||
Associates & JCEs | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other income | 1,134 | 1,103 | 1,175 | 1,256 | 1,340 | ||||||||||||||
Earnings before tax | 4,333 | 4,066 | 4,654 | 5,395 | 6,297 | ||||||||||||||
Income tax | -848 | -846 | -968 | -1,123 | -1,310 | ||||||||||||||
Net profit after tax | 3,484 | 3,220 | 3,686 | 4,273 | 4,987 | ||||||||||||||
Minority interests | -80 | -72 | -154 | -182 | -218 | ||||||||||||||
Other items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Preferred dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Normalised NPAT | 3,404 | 3,148 | 3,532 | 4,091 | 4,768 | ||||||||||||||
Extraordinary items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Reported NPAT | 3,404 | 3,148 | 3,532 | 4,091 | 4,768 | ||||||||||||||
Dividends | -1,020 | -1,236 | -1,143 | -1,283 | -1,486 | ||||||||||||||
Transfer to reserves | 2,384 | 1,912 | 2,389 | 2,808 | 3,283 | ||||||||||||||
Valuations and ratios | |||||||||||||||||||
Reported P/E (x) | 23.7 | 25.6 | 22.8 | 19.7 | 16.9 | ||||||||||||||
Normalised P/E (x) | 23.7 | 25.6 | 22.8 | 19.7 | 16.9 | ||||||||||||||
FD normalised P/E (x) | 23.7 | 25.6 | 22.8 | 19.7 | 16.9 | ||||||||||||||
Dividend yield (%) | 1.3 | 1.5 | 1.4 | 1.6 | 1.8 | ||||||||||||||
Price/cashflow (x) | 11.8 | 10.0 | 9.8 | 8.6 | 7.8 | ||||||||||||||
Price/book (x) | 5.6 | 4.9 | 4.3 | 3.7 | 3.2 | ||||||||||||||
EV/EBITDA (x) | 11.5 | 11.0 | 9.8 | 8.5 | 7.2 | ||||||||||||||
EV/EBIT (x) | 24.2 | 26.3 | 22.2 | 18.4 | 15.0 | ||||||||||||||
Gross margin (%) | 21.6 | 21.5 | 21.5 | 21.7 | 21.8 | ||||||||||||||
EBITDA margin (%) | 6.5 | 6.0 | 6.1 | 6.2 | 6.4 | ||||||||||||||
EBIT margin (%) | 3.1 | 2.5 | 2.7 | 2.9 | 3.1 | ||||||||||||||
Net margin (%) | 3.2 | 2.7 | 2.7 | 2.9 | 3.0 | ||||||||||||||
Effective tax rate (%) | 19.6 | 20.8 | 20.8 | 20.8 | 20.8 | ||||||||||||||
Dividend payout (%) | 30.0 | 39.3 | 32.4 | 31.4 | 31.2 | ||||||||||||||
ROE (%) | 26.5 | 20.4 | 20.1 | 20.3 | 20.5 | ||||||||||||||
ROA (pretax %) | 11.5 | 9.3 | 10.0 | 11.0 | 12.1 | ||||||||||||||
Growth (%) | |||||||||||||||||||
Revenue | 10.3 | 10.5 | 9.5 | 10.5 | 9.7 | ||||||||||||||
EBITDA | 10.4 | 3.3 | 10.5 | 12.9 | 12.8 | ||||||||||||||
Normalised EPS | 19.2 | -7.5 | 12.2 | 15.8 | 16.6 | ||||||||||||||
Normalised FDEPS | 19.2 | -7.5 | 12.2 | 15.8 | 16.6 | ||||||||||||||
Source: Company data, Verdhana estimates |
Cashflow statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY23 | FY24 | FY25F | FY26F | FY27F | ||||||||||||||
EBITDA | 6,913 | 7,138 | 7,885 | 8,905 | 10,049 | ||||||||||||||
Change in working capital | -1,291 | 177 | 199 | 391 | 403 | ||||||||||||||
Other operating cashflow | 1,195 | 748 | 102 | 32 | -58 | ||||||||||||||
Cashflow from operations | 6,817 | 8,063 | 8,187 | 9,328 | 10,394 | ||||||||||||||
Capital expenditure | -4,725 | -5,056 | -5,724 | -6,016 | -6,318 | ||||||||||||||
Free cashflow | 2,092 | 3,007 | 2,462 | 3,312 | 4,077 | ||||||||||||||
Reduction in investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Net acquisitions | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Dec in other LT assets | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Inc in other LT liabilities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Adjustments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
CF after investing acts | 2,092 | 3,007 | 2,462 | 3,312 | 4,077 | ||||||||||||||
Cash dividends | -1,020 | -1,236 | -1,143 | -1,283 | -1,486 | ||||||||||||||
Equity issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Debt issue | -1,510 | -63 | 0 | 0 | 0 | ||||||||||||||
Convertible debt issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Others | 694 | -937 | 0 | 0 | 0 | ||||||||||||||
CF from financial acts | -1,836 | -2,236 | -1,143 | -1,283 | -1,486 | ||||||||||||||
Net cashflow | 256 | 771 | 1,319 | 2,029 | 2,591 | ||||||||||||||
Beginning cash | 3,819 | 4,075 | 4,845 | 6,164 | 8,194 | ||||||||||||||
Ending cash | 4,075 | 4,845 | 6,164 | 8,194 | 10,784 | ||||||||||||||
Ending net debt | -2,372 | -3,350 | -4,620 | -6,598 | -9,135 | ||||||||||||||
Balance sheet (IDRbn) | |||||||||||||||||||
As at 31 Dec | FY23 | FY24 | FY25F | FY26F | FY27F | ||||||||||||||
Cash & equivalents | 4,075 | 4,845 | 6,164 | 8,194 | 10,784 | ||||||||||||||
Marketable securities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Accounts receivable | 2,812 | 3,231 | 3,252 | 3,568 | 3,892 | ||||||||||||||
Inventories | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other current assets | 10,440 | 12,265 | 12,746 | 14,003 | 15,287 | ||||||||||||||
Total current assets | 17,326 | 20,341 | 22,162 | 25,764 | 29,964 | ||||||||||||||
LT investments | 767 | 780 | 780 | 780 | 780 | ||||||||||||||
Fixed assets | 8,053 | 9,002 | 10,010 | 10,920 | 11,755 | ||||||||||||||
Goodwill | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other intangible assets | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other LT assets | 8,101 | 8,676 | 9,104 | 9,531 | 9,955 | ||||||||||||||
Total assets | 34,246 | 38,798 | 42,057 | 46,995 | 52,454 | ||||||||||||||
Short-term debt | 1,639 | 1,423 | 1,472 | 1,524 | 1,578 | ||||||||||||||
Accounts payable | 0 | 0 | 13,649 | 15,049 | 16,478 | ||||||||||||||
Other current liabilities | 15,624 | 18,045 | 5,097 | 5,662 | 6,243 | ||||||||||||||
Total current liabilities | 17,263 | 19,469 | 20,218 | 22,234 | 24,299 | ||||||||||||||
Long-term debt | 64 | 72 | 72 | 72 | 72 | ||||||||||||||
Convertible debt | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other LT liabilities | 1,215 | 1,562 | 1,682 | 1,796 | 1,907 | ||||||||||||||
Total liabilities | 18,541 | 21,102 | 21,972 | 24,102 | 26,278 | ||||||||||||||
Minority interest | 1,232 | 1,318 | 1,318 | 1,318 | 1,318 | ||||||||||||||
Preferred stock | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Common stock | 2,895 | 2,895 | 2,895 | 2,895 | 2,895 | ||||||||||||||
Retained earnings | 11,159 | 13,116 | 15,505 | 18,313 | 21,596 | ||||||||||||||
Proposed dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other equity and reserves | 419 | 366 | 366 | 366 | 366 | ||||||||||||||
Total shareholders' equity | 14,473 | 16,378 | 18,767 | 21,575 | 24,857 | ||||||||||||||
Total equity & liabilities | 34,246 | 38,798 | 42,057 | 46,995 | 52,454 | ||||||||||||||
Liquidity (x) | |||||||||||||||||||
Current ratio | 1.00 | 1.04 | 1.10 | 1.16 | 1.23 | ||||||||||||||
Interest cover | 37.6 | 157.9 | – | – | – | ||||||||||||||
Leverage | |||||||||||||||||||
Net debt/EBITDA (x) | net cash | net cash | net cash | net cash | net cash | ||||||||||||||
Net debt/equity (%) | net cash | net cash | net cash | net cash | net cash | ||||||||||||||
Per share | |||||||||||||||||||
Reported EPS (IDR) | 81.97 | 75.81 | 85.06 | 98.52 | 114.83 | ||||||||||||||
Norm EPS (IDR) | 81.97 | 75.81 | 85.06 | 98.52 | 114.83 | ||||||||||||||
FD norm EPS (IDR) | 81.97 | 75.81 | 85.06 | 98.52 | 114.83 | ||||||||||||||
BVPS (IDR) | 348.55 | 394.41 | 451.94 | 519.56 | 598.62 | ||||||||||||||
DPS (IDR) | 24.57 | 29.77 | 27.53 | 30.89 | 35.78 | ||||||||||||||
Activity (days) | |||||||||||||||||||
Days receivable | 9.1 | 9.4 | 9.1 | 8.7 | 8.7 | ||||||||||||||
Days inventory | 0.0 | 0.0 | 0.0 | 0.0 | |||||||||||||||
Days payable | 60.3 | 0.0 | 24.5 | 46.7 | 46.9 | ||||||||||||||
Cash cycle | -51.3 | 9.4 | -15.4 | -38.0 | -38.2 | ||||||||||||||
Source: Company data, Verdhana estimates |
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Rating Remains | Buy |
Target price Reduced from IDR 3,600 | IDR 2,350 |
Closing price 21 March 2025 | IDR 1,940 |
Implied upside | +21.1% |
Market Cap (USD mn) | 4,883.8 |
ADT (USD mn) | 5.7 |
M cap (USDmn) | 4,883.8 |
Free float (%) | 47.3 |
3-mth ADT (USDmn) | 5.7 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | -22.7 | -30.2 | -33.1 |
Absolute (USD) | -23.6 | -31.5 | -36.5 |
Rel to Jakarta Stock Exchange Composite Index | -14.7 | -19.8 | -18.4 |
Jody Wijaya (jody.wijaya@verdhana.id)
Sandy Ham (sandy.ham@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)